Kornimate/medical-research-clean huggingface dataset:
gut permeability assessment in celiac and gluten sensitive children

Conditions: Celiac Disease

Summary: this study will assess the effect of gluten on gut barrier function. investigators at the mayo clinic have developed a new gut permeability test using rhamnose (sugar \& water solution), and are hoping to prove its effectiveness in a clinical setting.

the aim of this study is to assess effect of gluten on the gut barrier function in patients at high risk for celiac disease and non-celiac gluten sensitivity (ncgs) patients. this study will assess the gut permeability in three groups of patients 1) children who are at high risk for developing celiac disease (cd) (siblings of patients with celiac disease), 2) children who are self-diagnosed with ncgs and 3) control group of patients matched for age and gender. patients will undergo celiac serologic and genetic testing, after which the rhamnose test will be performed to assess the presence of increased gut permeability.

Eligibility criteria:
high risk group: * sibling with a confirmed diagnosis of celiac disease * no history celiac disease or any other bowel disease non-celiac gluten sensitivity group: * self-diagnosis of gluten sensitivity * no history of celiac disease or other bowel disease healthy group: * absence of celiac disease or any other bowel disease * no sensitivity to gluten

Keywords: celiac gluten sensitivity permeability non-celiac gluten intolerance gastrointestinal diseases digestive system diseases
comparison of dry needling and thera gun treatment on trapezius muscle active trigger points.

Conditions: Neck Pain

Summary: comparison of dry needling and thera gun on treatment of active trigger points of trapezius muscle, pain threshold and range of motion of neck.

chronic neck pain related to the myo-facial systems from local muscle fiber contractions referred to "myo-facial trigger points" (mtrps).mtrps are highly sensitive spots that lie in the skeletal muscle, and are diagnosed with mechanical pressure, they can also develop as referral pain in a specific pattern. although mtrps are found in all muscle groups, they are more prevalent in the upper quarter postural muscles, especially the upper trapezius muscle. data will be collected from both gender patients having active trigger points in trapezius muscles. then patients will be divided randomly into two groups. all patient will be given conventional treatment and then group a will be given treatment with thera gun and group b will be given dry needling treatment and then will compare effects of both. to date, a wide range of physical therapy interventions have been suggested to address mtrps including manual therapies (massage, stretching, myofascial release), electrotherapy modalities (surface heat, ultrasound, transcutaneous electrical nerve stimulator and laser therapy) and invasive techniques such as dry needling (dn) but none of study is done on the effectiveness of facial gun in decreasing pain intensity and increasing range of motion and none of study compare the effect of dry needling with facial gun. so, this study will determine the effect of facial gun on pain intensity and range of motion and compare that effect with dry needling.

Eligibility criteria:
inclusion criteria: * diagnosed with cervical pain due to active trigger points of trapezius muscle * numeric pain rating scale\> 3 exclusion criteria: * any previous history of trauma or surgery * spondylitis * carcinoma * tuberculosis of spine * diagnosed with cervical pain \& stiffness due to disc herniation, radiculopathy or any other cervical malignancy

Keywords: trapezius trigger points range of motion pain threshold thera gun dry needling
an open-label pilot study of vtx2735 in recurrent pericarditis

Conditions: Recurrent Pericarditis

Summary: this is a study to understand if taking vtx2735 is safe and effective in participants diagnosed with recurrent pericarditis (rp). approximately 30 patients will take vtx2735. the study consists of a 30-day screening period (to see if a participant qualifies for the study), a 6-week open label treatment period (a participant receives active dose a), a 7-week extension treatment period (a participant meets criteria for continuing and receives active dose a) and a 14-day follow-up period.


Eligibility criteria:
inclusion criteria: * participants are male or female ≥ 18 years up to ≤ 75 years of age. * capable of giving signed informed consent and able to comply with the protocol * previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event * ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks. * crp by local laboratory assessment prior to first dose of study treatment (participants with crp ≤ 1 mg/dl must be receiving corticosteroid treatment for rp and have evidence of pericardial inflammation) * pericarditis pain score ≥ 4 based on the 11-point nrs. * stable doses of nsaids, colchicine, and/or oral corticosteroids (if receiving these treatments) exclusion criteria: * current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases. * history of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency. * clinically important history of a medical disorder that would compromise safety or data quality, per the investigator's judgment.

Keywords: ventyx zomagen recurrent pericarditis vtx2735 nlrp3 inhibitor nlrp3 inflammasome
daptomycin pharmacokinetics in critically ill patients undergoing continuous veno-venous hemodiafiltration, a dose finding study

Conditions: Gram-Positive Bacterial Infections

Summary: daptomycin kinetics in crrt * trial with medicinal product


Eligibility criteria:
inclusion criteria: * male or female of 18 years or older * females: negative pregnancy test * hospitalisation in the medical icu * high suspicion or evidence of gram-positive infections requiring antibiotic therapy * subjects receiving standard antibiotic treatment for gram-positive infection * evidence of renal failure * clinical necessity for continuous renal replacement therapy * written informed consent signed by the patient or a next of kin and an independent physician in case the patient is not able to sign. exclusion criteria: * skeletal muscle disorders or cpk levels of \> 2 x uln * history of hypersensitivity to the drug * participation in another study * subjects with a history of muscle disease * patients with severe liver function impairment (child * life expectancy of less than 5 days

Keywords: gram positive infection and crrt
prevalence and factors associated with postoperative hypothermia in mulago hospital

Conditions: Post Operative Hypothermia

Summary: patient's sublingual temperature was measured postoperatively on entry to the recovery room.

adult patients who underwent non-neurological and non-cardiac surgery had their sublingual temperature measured postoperatively on entry to the recovery room.

Eligibility criteria:
inclusion criteria: * all patients of 18 years and above, undergoing surgery and anaesthesia lasting longer than 30minutes. * all patients of 18 years and above, undergoing elective and emergency non cardiac and non-neurological operations in mulago national referral hospital. exclusion criteria: * patients with contraindications to measurement of sublingual temperature
a study to provide continued access to study drug to children and adolescents who have completed clinical studies involving gilead hiv treatments

Conditions: HIV-1-infection

Summary: the goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (hiv-1) who completed their participation in an applicable parent study and to monitor for adverse events. the primary objectives of this study are as follows: * to provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (b/f/taf) for participants who completed a gilead parent study evaluating drugs for hiv treatment. * to evaluate the safety of the study drug(s) in participants with hiv-1.


Eligibility criteria:
key inclusion criteria: * completed an applicable parent study: gs-us-292-0106, gs-us-380-1474, gs-us-311-1269, gs-us-216-0128, or co-us-380-5578 and gave consent to study participation. key exclusion criteria: * individuals planning to switch to b/f/taf on day 1 cannot have plasma hiv rna ≥ 50 copies/ml during the last parent study visit prior to screening/day 1 visit. * note: individuals planning to switch after day 1 must not have plasma hiv rna ≥ 50 copies/ml (or detectable hiv-1 rna level according to the local assay being used if the limit of detection is ≥ 50 copies/ml). * individuals planning to switch to b/f/taf must not have any ongoing grade 3 or 4 drug-related ae or clinically relevant grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of b/f/taf prior to treatment switch. * for those on b/f/taf or planning to switch to b/f/taf: previous treatment discontinuation of any component of b/f/taf due to toxicity or intolerance. * for those planning to switch to b/f/taf: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients. * ongoing treatment with or prior use of any prohibited medications. note: other protocol defined inclusion/exclusion criteria may apply.
standard versus high-dose trivalent inactivated flu vaccine in pediatric acute lymphoblastic leukemia patients

Conditions: Pediatric Patients With Acute Lymphoblastic Leukemia

Summary: this is a phase i safety and immunogenicity trial comparing high-dose (hd)trivalent inactivated influenza vaccine (tiv) to standard dose (sd) tiv in pediatric patients with acute lymphoblastic leukemia.


Eligibility criteria:
inclusion criteria: * pediatric patients with standard or high risk acute lymphoblastic leukemia. * must be in 1st complete remission. * must be 4 weeks into maintenance therapy. * 17 years of age, inclusive. * available for duration of study. exclusion criteria: * history of hypersensitivity to previous influenza vaccination or hypersensitivity to eggs/egg protein. * history of guillain-barre syndrome. * evidence of relapsed disease. * have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render them unable to meet the requirements of the protocol. * have any condition that the investigator believes may interfere with successful completion of the study. * history of receiving 2010 - 2011 influenza vaccine. * pregnant female. * history of proven influenza disease after september 1, 2010.
the assessment of tci633 probiotics on pain relief and functional improvement in osteoarthritis

Conditions: Osteoarthritis

Summary: to assess tci633 probiotics on pain relief and functional improvement in osteoarthritis

this is a double-blind and randomized study. subjects are informed to consume the samples before meals in the morning every day. the clinical and radiological diagnosis of osteoarthritis of the knee is evaluated by the doctor. the blood samples and questionnaires are collected at every visit of the trial.

Eligibility criteria:
inclusion criteria 1. osteoarthritis patients with joint pain or discomfort (diagnosed by the physician for severe classification of the kellgren-lawrence grade 1-3) 2. without heart, liver, kidney, endocrine and other major organic diseases (patient return) exclusion criteria 1. with heart, liver (got and gpt values are 3-fold higher than the standard maximum), kidney (estimated creatinine clearance less than 25 ml/min), endocrine and other major organic diseases (patient return) 2. people with mental illness
randomized study of z-100 plus radiation therapy to treat cervical cancer

Conditions: Cervical Cancer

Summary: this study is a phase iii, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of z-100 with primary uterine cervical cancer on radiotherapy. the study will use a central randomization with a dynamic allocation using biased coin minimization.


Eligibility criteria:
inclusion criteria: 1. figo stage (2008): iiib, cervical cancer; 2. pathologically confirmed squamous cell carcinoma of the cervix; 3. patients with treatment-naive cervical cancer; 4. patients without enlargement (≥15 mm in the short axis) in the lower abdominal para-aortic lymph node confirmed by ct scanning (patients need not repeat ct scan at screening if ct data \[film or electronic image\] within 30 days before informed consent are available and can be provided for central imaging assessment); 5. patients ≥21, ≤79 years of age at informed consent; 6. patients for whom it is considered possible to carry out intracavitary radiation in radiotherapy; 7. eastern cooperative oncology group performance status: 0-2; 8. patients with the following organ functions; (1) wbc ≥3,000/mm3; (2) platelet count ≥100,000/mm3; (3) hemoglobin ≥9.5 g/dl (correction by blood transfusion is allowed); (4) total bilirubin ≤ three (3) times the upper limit of reference value at the clinical testing laboratory; (5) ast, alt ≤ three (3) times the upper limit of reference value at the clinical testing laboratory; (6) renal function: 1. if combination therapy with cisplatin is planned, creatinine clearance: ≥50 ml/min; 2. if combination therapy with cisplatin is not planned, creatinine ≤ twice (2) the upper limit of reference value at the clinical testing laboratory; 9. patients who are willing to give informed consents. "
sleep and quality of life in patients with glycogen storage disease on standard versus modified uncooked cornstarch

Conditions: Glycogen Storage Disease Type IA; Glycogen Storage Disease Type IB; Glycogen Storage Disease Type III; Glycogen Storage Disease Type 0

Summary: the aim of the present study is to determine if there is a change in quality and quantity of sleep perceived by adults and children with gsd and their parents while starting a modified uccs (glycosade) to prevent nocturnal hypoglycemia. the investigators also aim to evaluate if there is a change in quality of life perceived by adults and children and their parents with glycosade.

this is a prospective cohort study. patients above 2 years old and their parents (for children only) will be enrolled during their usual follow-up. parents will be asked to complete a quality of sleep questionnaire (as it pertains to both child and parent) relating to the past month on their current dietary regimen (standard uccs) and a quality of life questionnaire (as it pertains to the child only). parents will then complete a sleep diary (for both child and parent) and both child and parent will wear an actigraph that will record movements during sleep over a 1 week period. adult gsd patients will complete their own questionnaires. following this first assessment, they will be hospitalised over a 24 hour period as part of standard of care to start the modified uccs, glycosade, under supervision and with a continuous glucose monitoring (cgm) sensor. following hospitalization, the family will return home. glucose will be monitored with the aid of the cgm sensor for 5 to 7 days. the actigraphy and the sleep diary will be repeated after 2 weeks (for 1 week) while on glycosade. one month after starting the modified uccs, questionnaires on quality of sleep and quality of life will be repeated.

Eligibility criteria:
inclusion criteria: * patients of ≥ 2 years old with a diagnostic of gsd 0, i, iii, vi, ix or xi based on a liver biopsy, mutation in the appropriate gene or clinical evidence of gsd with a positive familial history * medical history of fasting hypoglycemia * currently taking standard uccs * with a stable condition * followed in gsd clinics at the montreal children's hospital and the hôpital st-luc * with informed consent obtained exclusion criteria: * continuous overnight feeds
cpasma: is there an improvement in asthma in patients with both asthma and osas treated with cpap?

Conditions: Asthma; Obstructive Sleep Apnea Syndrome

Summary: the cpasma trial is a descriptive, prospective, multicentre clinical trial, with a before/after continuous positive airway pressure (cpap) assessment in participating patients. it aims to answer the following question: is there an improvement in asthma in those patients with both asthma and obstructive sleep apnoea syndrome (osas) treated with cpap after six months?. it is hypothesized that treatment of osas with cpap in patients with both osas and asthma concommitantly, may have a beneficial effect also on asthma outcomes. this clinical effect in asthma could be assessed objectively by applying validated questionnaires for quality of life and asthma control.

full protocol in spanish, available upon request

Eligibility criteria:
inclusion criteria: * adult patients (18 to 70 yrs.) with asthma who require treatment with cpap because of osas (rdi\> = 20 events per hour) exclusion criteria: * unstable or severe comorbidity, * patients in treatment with drugs that interfere with the clinical course of asthma and/or osas, * cognitive/psychiatric disorders that preclude patient participation/cooperation, * copd or other lung disease accompanied by chronic airflow limitation, and * any clinical condition considered severe enough by the investigators to preclude all the diagnostic and therapeutic procedures outlined in this protocol.

Keywords: asthma obstructive sleep apnea syndrome
using multiparametric flow cytometry to detect peripheral blood and bone marrow leukaemia stem cells for relapse prediction in p-aml

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia

Summary: leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. the group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.


Eligibility criteria:
inclusion criteria: * newly diagnoses candidates with acute myeloid leukemia. * lower than or equal to 18 years-old; * subjects are able to provide written informed consent. exclusion criteria: * subjects who cannot comply with the study; * subjects with severe cardiac disease (ejection fraction\ 34umol/l, alt and ast\>1.5×upper limit normal) or kidney disease (serum creatinine\>130umol/l). * subjects with severe infection. * subjects with other conditions that cannot receive chemotherapy or transplantation.
post-stroke perturbation training

Conditions: Stroke

Summary: following a stroke, many individuals have a high risk of falls, which can negatively influence quality of life. unfortunately, current treatments have not effectively addressed this problem. this study investigates whether two methods of delivering mechanical perturbations during walking have the potential to improve post-stroke walking balance and reduce real-world fall incidence.


Eligibility criteria:
inclusion criteria: * experience of a stroke at least 6 months prior to participation * self-reported experience of a fall in the previous year, and/or a fear of falling * gait speed of at least 0.2 m/s * ability to walk on a treadmill without a cane or walker * provision of informed consent exclusion criteria: * evidence of cerebellar damage * resting blood pressure higher than 220/110 mm hg * history of unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living * preexisting neurological disorders or dementia * legal blindness or severe visual impairment * history of dvt or pulmonary embolism within 6 months * uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions * orthopedic injuries or conditions (e.g. joint replacements) in the lower extremities with the potential to alter the gait pattern
myorelaxant effect of bee venom(bv) topical skin application in patients with rdc/tmd ia and ib

Conditions: Other Disorders of Muscle in Diseases Classified Elsewhere

Summary: topical application of bv ointment in patients with research diagnostic criteria/temporomandibular disorder 1a and 1b (rdc/tmd) in experimental group, compared to placebo (vaseline) in control group.application was repeated 3 times a day, during 14 days. surface electromyography (emg) was used to measure masseter rest tonus and maximal voluntary contraction tonus. pain intensity was also analysed in vas scale. effectiveness of bv was compared with placebo in masseter myofascial pain in patients with tmd

the aim of the study was evaluation of myorelaxant action of bee venom(bv) ointment, comparing to placebo.parallel group, randomized double blinded trial was performed, including 79 patients with painful rdc/tmd 1a and 1b. muscle tension was measured twice (ton1 and ton2) in rest muscle tonus (rmt) and maximal muscle contraction (mmc) on both sides right and left, with easy train myo emg (version 3.1). pain intensity was also analysed in vas scale

Eligibility criteria:
inclusion criteria: * rdc/tmd 1a and 1b * agreement to participate in the experimental study exclusion criteria: * bee venom allergy * hyperactivity on bee products * positive anamnesis of anaphylactic reaction after bee bites * skin wounds with skin surface discontinuation * rdc/tmd 2 and 3

Keywords: tmd bee venom muscle tension muscle pain
longevity in russia

Conditions: LONGEVITY 1; Frailty; Aging; Age-related Cognitive Decline; Aging Disorder

Summary: this is an observational cohort study of long-living adults (participants aged 90 and above) from the central federal district of russia. the study seeks to determine the genetic and cellular and molecular determinants of healthy longevity and to assess the impact of lifestyle and socioeconomic and environmental factors on healthy longevity. the study is expected to result in the development of a panel of markers of healthy longevity and/or a model of healthy aging based on the analysis of all factors under consideration.

the study involves a long-term observation of a cohort of long-living adults. during the first visit, a medical professional will take a detailed medical history and perform a comprehensive geriatric assessment (for 15 geriatric syndromes), and physical examination. the participants will have their biomaterials sampled for basic and extended blood biochemistry testing, telomere length measurement, common urine tests and subsequent biobanking and additional studies: whole genome sequencing, dna methylation analysis, transcriptome analysis, and 16s rna sequencing of stool and saliva. follow-up checks will be carried out once a year by phone or during additional visits. the study seeks to identify the genetic, epigenetic, and metagenomic determinants associated with the successful and unsuccessful aging phenotypes, mortality, and survival in long-living individuals.

Eligibility criteria:
inclusion criteria: * informed consent * 90 years of age or above exclusion criteria: * refusal to participate or to provide informed consent; * any other criteria deemed reasons for exclusion by the principal investigator.